Psychoactive drugs

Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Psychoactive drugs, Amines, Entheogens, Ayahuasca, N,N-Dimethyltryptamine, Hallucinations, Psychedelic drug
Tuesday, July 27, 2021 - 12:00pm

Toronto, Ontario--(Newsfile Corp. - July 27, 2021) - Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Algernon Pharmaceuticals Inc.  (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19, and Pharmadrug, a Biotech Company Focused on the R&D of Natural Based Medicines are pleased to announce the DMT Conference.

Key Points: 
  • The two-day virtual conference is to take place on September 9-10th 2021, starting at 12 pm EDT.
  • Join us as we take a scientific deep dive into the dynamic field of DMT therapeutics, with expert panels and engaging discussions.
  • Our Molecular Masterclasses are a speaker series designed for deep dives into the world's favourite psychoactive and psychedelic substances.
  • Each event will explore one drug, and feature a curated group of industry experts and thought leaders from around the world.

Clever Leaves and Biopharmaceutical Research Company to Partner for Landmark Cannabis Research Study in Collaboration with the University of California, Davis

Entheogens, Euphoriants, Medicinal plants, Cannabis, Cannabis smoking, Clever, Plants, University of California, Davis, Psychoactive drugs, Geography of California
Tuesday, July 27, 2021 - 1:00pm

NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S., today announced a joint partnership with the intent to study the DNA sequence variation of three Clever Leaves’ cannabis cultivars as part of their Project Change Lives campaign. The University of California, Davis (“UC Davis”), through an accepted research sponsorship from BRC, will lead the extraction and analysis of DNA to elucidate genetic variants taken from various genetic lines of Cannabis sativa.

Key Points: 
  • The initiative is part of Project Change Lives; Clever Leaves $25M product pledge to aid cannabis research in the U.S.
  • UC Davis will be the first major research institution to collaborate in the investigation of Clever Leaves Colombian and Portuguese, pharmaceutical-grade cannabis as part of Project Change Lives.
  • We are honored to collaborate with the UC Davis Plant Science department, said Kyle Detwiler, CEO of Clever Leaves.
  • To eliminate an additional impediment to the advancement of scientific knowledge around cannabis, this research material will be provided at no cost to Clever Leaves research partners.

Flor Americas Partners with Biosintex Laboratorios to Supply Cannabinoids for Argentina’s Pharmaceutical Market

Biotechnology, Alternative medicine, Health, Pharmaceutical, Medical Supplies, Cannabis, Cannabis smoking, Entheogens, Euphoriants, Legality of cannabis, Psychoactive drugs, Medical specialties
Tuesday, July 27, 2021 - 12:17pm

Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.

Key Points: 
  • Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.
  • During the past 20 years, Biosintex Laboratorios has earned a reputation for developing and manufacturing world-class pharmaceuticals.
  • Recently, Biosintex Laboratorios received authorization to import CBD from a producer within Flor Americas network.
  • Biosintex Laboratorios is an Argentine pharmaceutical company that develops and manufactures medicinal products with more than 20 years of experience in the market.

Jane Technologies Enters Canadian Market Through Partnership with Leading Canadian Retailer, High Tide

E-commerce, Electronics industry, Non-store retailing, Supply chain management, Cannabis, Marketplace, Industry economics), Economic taxonomy, Psychoactive drugs
Tuesday, July 27, 2021 - 12:00pm

Our partnership with High Tide is a testament to Jane's e-commerce solutions, and ability to integrate across nearly 90 storefronts without disruption."

Key Points: 
  • Our partnership with High Tide is a testament to Jane's e-commerce solutions, and ability to integrate across nearly 90 storefronts without disruption."
  • Jane is the trusted e-commerce partner for over 2,000 dispensaries and brands across 34 U.S. markets and the Canadian market.
  • Jane is the cannabis industry's first fully automated e-commerce solution, powering 2,000+ dispensaries and brands across 34 state markets and the Canadian market.
  • For more information about High Tide Inc., please visit www.hightideinc.com and its profile page on SEDAR at www.sedar.com .

BC Craft Supply Co Debuts Grizzlers Brand in Alberta Through Revolutionary $1 “Buck a Joint” S^MPLE by AHLOT™ Program.

Entheogens, Psychoactive drugs, Cannabis smoking, Euphoriants, Medicinal plants, Drug culture, Cannabis culture, Cannabis, Effects of cannabis
Tuesday, July 27, 2021 - 12:00pm

The S^MPLE by AHLOT program brings traditional CPG sampling to the cannabis industry, in a compliant manner.

Key Points: 
  • The S^MPLE by AHLOT program brings traditional CPG sampling to the cannabis industry, in a compliant manner.
  • BC Craft Supply Co Ltd is a diversified wellness company advancing cannabinoid and psychedelic innovation and psychotherapy.
  • BC Craft works with local artists cross-sector and remains fervently committed to keeping the art, technique, and purity of their pursuit.
  • For AHLOT media information:
    THE CANADIAN SECURITIES EXCHANGE (THE CSE) HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE.

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Psychoactive drugs, Entheogens, Branches of biology, NMDA receptor antagonists, Indole alkaloids, Drug rehabilitation, Ibogaine, Tabernanthe iboga, Legal status of ibogaine by country
Tuesday, July 27, 2021 - 8:30am

During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.

Key Points: 
  • During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.
  • As first announced on July 13, 2021, MINDCURE has also filed patent applications for two routes of chemical synthesis of ibogaine.
  • Ibogaine is a psychoactive substance that can be found naturally in the roots of the iboga tree, which grows in Africa.
  • "We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes," said Kelsey Ramsden, President and CEO of MINDCURE.

Curaleaf International Launches Second Medical Cannabis Flower Product for UK Market

Alternative medicine, Health, Science, Pharmaceutical, Research, Medicinal plants, Psychoactive drugs, Health sciences, Herbalism, Cannabis smoking, Entheogens, Euphoriants, Branches of biology, Curaleaf, Cannabis, Medical cannabis, Effects of cannabis
Tuesday, July 27, 2021 - 7:00am

Curaleaf International (formerly EMMAC Life Sciences Group), (Curaleaf International), Europes largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market.

Key Points: 
  • Curaleaf International (formerly EMMAC Life Sciences Group), (Curaleaf International), Europes largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market.
  • The new products are being manufactured in the UK and will be an extension to Curaleaf Internationals existing range of medical cannabis flower and oil products.
  • Antonio Costanzo, CEO of Curaleaf International, commented: We are very pleased to extend our range of medical cannabis products for the UK market.
  • As a market leader, Curaleaf International is focused on solving the key patient and physician challenges relating to the price, accessibility, and sustainability of medical cannabis products.

Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor

Hallucinations, Psychoactive drugs, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Hallucinogen, Branches of biology
Monday, July 26, 2021 - 2:43pm

Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals and is one of the most cited researchers in the medical application of psychedelic compounds.

Key Points: 
  • Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals and is one of the most cited researchers in the medical application of psychedelic compounds.
  • Tryp is also announcing the appointment of Daniel Clauw, M.D., as a member of the Scientific Advisory Board.
  • We welcome their continued scientific leadership as we advance the development of our PFN program toward approved therapies for patients."
  • Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

Endexx Corporation and DJ Khaled’s BLESSWELL Shows Strong Promise in the CBD Wellness Sector Within First Months of Debut

Entheogens, Euphoriants, Psychoactive drugs, Medicinal plants, Branches of biology, Drugs, Herbs, Herbalism, Cannabis sativa, Cannabis, Hemp, Medical cannabis
Tuesday, July 27, 2021 - 1:00am

Cave Creek, AZ, July 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- In May of 2021, Endexx Corporation (OTC: EDXC), the leading producer and manufacturer of hemp-derived CBD wellness products, and legendary music artist DJ Khaled, officially joined forces to launch BLESSWELL™. The clean and natural CBD-infused men’s grooming line is designed to be an essential toolkit for a man's complete at-home self-care needs. 

Key Points: 
  • The clean and natural CBD-infused mens grooming line is designed to be an essential toolkit for a man's complete at-home self-care needs.
  • Taking place in early June, BLESSWELL partnered with iconic fashion brand, Von Dutch, to host a Summer Fridays Kickoff event in Hollywood, CA.
  • Celebrities, influencers, and media such as Terrence J., Sarunas J. Jackson, Rolling Stone, and Hypebeast attended the exclusive summer soiree.
  • Endexx Corporation, through its operating division CBD Unlimited, develops and distributes all-natural CBD products derived from cannabis sativa plant (Hemp), containing less than 0.01% THC.

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

Acura Pharmaceuticals, Euphoriants, Morphinans, Health care, Pharmaceuticals policy, Ketones, LTX, Acura, Hydromorphone, Pharmaceutical industry in China, Psychoactive drugs, Health
Monday, July 26, 2021 - 9:15pm

PALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (Agreement) regarding Acuras LIMITx LTX-03 product candidate with Abuse Deterrent Pharma, LLC (AD Pharma) to extend the FDA Acceptance Date for LTX-03 (NDA Acceptance Date) to February 28, 2022.

Key Points: 
  • PALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (Agreement) regarding Acuras LIMITx LTX-03 product candidate with Abuse Deterrent Pharma, LLC (AD Pharma) to extend the FDA Acceptance Date for LTX-03 (NDA Acceptance Date) to February 28, 2022.
  • Clinical studies with hydromorphone (LTX-04) demonstrated reductions in Cmax of up to 65% when up to 8 tablets were ingested.
  • Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse.
  • LIMITx is useful with products whose side effect risks can be mitigated by limiting exposure to a drug in overdose situations.